MANKIND - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.1
| Stock Code | MANKIND | Market Cap | 92,750 Cr. | Current Price | 2,247 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 52.5 | Book Value | 376 ₹ | Dividend Yield | 0.04 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,143 ₹ | DMA 200 | 2,244 ₹ |
| Chg in FII Hold | -1.10 % | Chg in DII Hold | 1.20 % | PAT Qtr | 513 Cr. | PAT Prev Qtr | 459 Cr. |
| RSI | 63.8 | MACD | 50.1 | Volume | 3,09,556 | Avg Vol 1Wk | 3,26,436 |
| Low price | 1,910 ₹ | High price | 2,727 ₹ | PEG Ratio | 6.24 | Debt to equity | 0.47 |
| 52w Index | 41.2 % | Qtr Profit Var | 24.5 % | EPS | 41.3 ₹ | Industry PE | 30.1 |
📈 Optimal Buy Price
Entry zone: ₹2,230–₹2,250, near DMA 50 & DMA 200 support. Avoid chasing above ₹2,270 unless volume expands beyond weekly average.
🎯 Exit Levels
- Profit-taking: ₹2,280–₹2,310 if momentum sustains
- Stop-loss: Below ₹2,215 (weakness under support)
⏳ Intraday Exit Guidance
If already holding, consider exiting if RSI dips below 61, price fails to hold above ₹2,230, or intraday volume momentum fades below 2.8 lakh with stagnant price action. Book profits near ₹2,280–₹2,310 if momentum slows.
✅ Positive
Strong quarterly PAT growth (₹459 Cr. → ₹513 Cr.), EPS at ₹41.3 reflects earnings strength, ROE at 13.9% and ROCE at 15% show healthy returns, DII inflows (+1.20%) support sentiment, and price trading above DMA 50 confirms short-term strength.
⚠️ Limitation
High valuation with P/E at 52.5 vs industry 30.1, PEG ratio at 6.24 indicates overvaluation relative to growth, FII outflows (-1.10%) weigh on sentiment, and dividend yield at 0.04% is negligible.
📉 Company Negative News
Foreign investor selling pressure and stretched valuations limit upside potential.
📊 Company Positive News
Strong quarterly profit growth of 24.5%, domestic institutional inflows, and technical momentum supported by RSI at 63.8 and MACD at 50.1.
🏭 Industry
Pharma sector average P/E at 30.1, Mankind trades at a premium (52.5). Sector outlook supported by demand for generics and specialty drugs, though valuations remain elevated.
🔎 Conclusion
Mankind is a strong intraday candidate with earnings momentum and technical strength but stretched valuations. Best suited for entries near ₹2,230–₹2,250 with exits around ₹2,280–₹2,310. Maintain strict stop-loss below ₹2,215 and monitor RSI/volume closely for intraday signals.